This article was updated on 1/25/2021.
The FDA accepted a 505(b)(2) New Drug Application (NDA) for INP104 (Trudhesa, Impel NeuroPharma) for the acute treatment of migraine headaches with or without aura in adults.
JANUARY 25, 2021
JANUARY 25, 2021
This article was updated on 1/25/2021.
The FDA accepted a 505(b)(2) New Drug Application (NDA) for INP104 (Trudhesa, Impel NeuroPharma) for the acute treatment of migraine headaches with or without aura in adults.